| Bioactivity | BTK-IN-23 is a BTK inhibitor (IC50: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC50s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997)[1]. |
| Invitro | BTK-IN-23 (化合物 3) 抑制 Jeko-1 细胞中的 BTK 自磷酸化，IC50 为 314 nM[1]。 Western Blot Analysis[1] Cell Line: |
| Name | BTK-IN-23 |
| CAS | 2573048-11-8 |
| Formula | C27H28N6O2 |
| Molar Mass | 468.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sean T. Toenjes, et al. Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. ACS Med. Chem. Lett. 2023. https://doi.org/10.1021/acsmedchemlett.2c00523 |
BTK-IN-23
CAS: 2573048-11-8 F: C27H28N6O2 W: 468.55
BTK-IN-23 is a BTK inhibitor (IC50: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC50s of 35.6 and 5.7 nM respecti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.